Zhang Li, Varma Nadimpalli Rs, Gang Zhang Z, Ewing James R, Arbab Ali S, Ali Meser M
Department of Neurology, Henry Ford Hospital, Detroit, MI 48202, USA.
Tumor Angiogenesis Laboratory, Georgia Cancer Center, Augusta University, Augusta, GA, USA.
J Nanomed Nanotechnol. 2016 Oct;7(5). doi: 10.4172/2157-7439.1000404. Epub 2016 Oct 28.
There is no available targeted therapy or imaging agent for triple negative breast cancer (TNBC). We developed a small-sized dendrimer-based nanoparticle containing a clinical relevant MRI contrast agent, GdDOTA and a NIR fluorescent dye, DL680. Systemic delivery of dual-modal nanoparticles led to accumulation of the agents in a flank mouse model of TNBC that were detected by both optical and MR imaging. fluorescence images, as well as fluorescence images of individual organs, demonstrated that nanoparticles accumulated into tumor selectively. A dual modal strategy resulted in a selective delivery of a small-sized (GdDOTA)42-G4-DL680 dendrimeric agent to TNBC tumors, avoiding other major organs.
目前尚无针对三阴性乳腺癌（TNBC）的靶向治疗方法或成像剂。我们开发了一种基于树枝状聚合物的小型纳米颗粒，其中包含临床相关的MRI造影剂钆喷酸葡胺（GdDOTA）和近红外荧光染料DL680。双模态纳米颗粒的全身给药导致这些试剂在TNBC的侧腹小鼠模型中积累，可通过光学和磁共振成像检测到。荧光图像以及各个器官的荧光图像表明，纳米颗粒选择性地积聚在肿瘤中。双模态策略导致小型（GdDOTA）42-G4-DL680树枝状试剂选择性递送至TNBC肿瘤，避免了其他主要器官。
